Organisations working on MS
| Rank | Organisation | Country | MS trials | Recruiting | MS papers 2021–2025 | Score |
|---|---|---|---|---|---|---|
| 1 | Biogen Makes interferon beta-1a, natalizumab, dimethyl fumarate and diroximel fumarate. Trials in the Trial Bank | United States | 239 | 3 | 142 | 96 |
| 2 | Novartis Makes fingolimod, siponimod and ofatumumab. Trials in the Trial Bank | Switzerland | 180 | 16 | 141 | 83 |
| 3 | Roche / Genentech Makes ocrelizumab (Ocrevus), the first therapy approved for PPMS. Trials in the Trial Bank | Switzerland | 84 | 12 | 154 | 68 |
| 4 | Merck KGaA (EMD Serono) Makes interferon beta-1a (Rebif) and cladribine (Mavenclad). Trials in the Trial Bank | Germany | 111 | 0 | 94 | 54 |
| 5 | Sanofi Makes teriflunomide and alemtuzumab. Developing tolebrutinib. Trials in the Trial Bank | France | 82 | 4 | 46 | 32 |
| 6 | Bristol Myers Squibb Makes ozanimod. Developing CAR-T therapy for MS. Trials in the Trial Bank | United States | 30 | 5 | 31 | 16 |
| 7 | Teva Pharmaceuticals Makes glatiramer acetate (Copaxone). Trials in the Trial Bank | Israel | 51 | 0 | 12 | 15 |
| 8 | Janssen (Johnson & Johnson) Makes ponesimod (Ponvory). Trials in the Trial Bank | Belgium | 10 | 0 | 27 | 11 |
| 9 | TG Therapeutics Makes ublituximab (Briumvi). Trials in the Trial Bank | United States | 16 | 9 | 3 | 4 |
| 10 | Immunic Therapeutics Developing vidofludimus calcium. Trials in the Trial Bank | Germany | 4 | 0 | 3 | 2 |
How the ranking works
Organisations are ranked only against others of the same type. Each gets a score out of 100. Half comes from the number of MS studies on ClinicalTrials.gov that list it as sponsor or collaborator. The other half comes from the number of MS papers on PubMed from 2021–2025 with an author at the organisation. Each half is measured against the highest count in that group.
The score measures activity, not quality or importance. A large company will register more trials than a small one, and a charity that funds research will often appear as a collaborator, not the sponsor. Name searches can miss studies or pick up unrelated ones. Every count links to the search behind it so you can check it.
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error